Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.52 |
| ▸ | CDC25B | P30305 | 3/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428606 | 1.00 | NQO2 (0.61) | NQO2CYP1A2CYP2A6TRPM4CDC25B | |
| SCHEMBL10381475 | 0.86 | MAPT (0.51) | NQO2CYP1A2CYP3A4MEN1KMT2A | |
| SCHEMBL30391379 | 0.80 | NQO2 (0.52) | NQO2CYP1A2CYP2A6TRPM4CDC25B | |
| SCHEMBL23043017 | 0.80 | NQO2 (0.52) | NQO2CYP1A2CYP2A6TRPM4CDC25B | |
| SCHEMBL27741807 | 0.80 | CDC25B (0.46) | CYP1A2CYP2A6CDC25BAKR1B1CYP3A4 | |
| SCHEMBL312277 | 0.80 | SMN1; SMN2 (0.53) | NQO2CYP1A2CYP3A4MEN1KMT2A | |
| SCHEMBL4421684 | 0.79 | NQO2 (0.50) | NQO2TRPM4CDC25BMEN1KMT2A | |
| SCHEMBL2201994 | 0.78 | CDC25B (0.50) | NQO2CYP1A2CYP2A6CDC25BAKR1B1 | |
| SCHEMBL29955307 | 0.78 | CDC25B (0.50) | NQO2CYP1A2CYP2A6CDC25BAKR1B1 | |
| SCHEMBL29469023 | 0.78 | CDC25B (0.50) | NQO2CYP1A2CYP2A6CDC25BAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180282257-A1 | Aromatic Monoester Compositions and Processes for Preparing Same | EXXONMOBIL CHEMICAL PATENTS INC. | 2018-10-04 | — | — | US | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12612387-B2 | RAS inhibitors and methods of using the same | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2026-04-28 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4476221-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-12-18 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2002044416-A2 | SULFONATED DIARYLRHODAMINE DYES AS FLUORESCENT LABELS | APPLERA CORPORATION (US) | 2002-06-06 | — | — | WO | disclosed |
| US-20020034761-A1 | Methods of labelling polynucleotides with dibenzorhodamine dyes | THE PERKIN-ELMER CORPORATION (US) | 2002-03-21 | — | — | US | disclosed |
| US-6326153-B2 | POLYNUCLEOTIDE SEQUENCING | THE PERKIN-ELMER CORPORATION | 2001-12-04 | — | — | US | disclosed |
| US-20010011139-A1 | Polynucleotides labeled with dibenzorhodamine dyes | THE PERKIN-ELMER CORPORATION | 2001-08-02 | — | — | US | disclosed |
| US-6221606-B1 | ENERGY TRANSFER DYE COMPRISING A DONOR DYE WHICH ABSORBS IGHT AND EMITS EXITATION ENERGY, AN ACCEPTOR DYE THE ABSORBS THE EXCITATION ENERGY AND FLUORESCES IN RESPONSE, AND A LINKER LINKING THE TWO DYES, AT LEAST ONE IS A DIBENZORHODAMINE DYE | THE PERKIN-ELMER CORPORATION | 2001-04-24 | — | — | US | disclosed |
| EP-1034221-A1 | DIBENZORHODAMINE DYES USEFUL AS FLUORESCENT LABELLING AGENTS | THE PERKIN-ELMER CORPORATION (US) | 2000-09-13 | — | — | EP | disclosed |
| US-6111116-A | FLUORESCENT LABELING REAGENTS | THE PERKIN-ELMER CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-6051719-A | FLUORESCENT LABELING REAGENTS | THE PERKIN-ELMER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| US-5936087-A | FLUORESCENT LABELS; DNA SEQUENCING | THE PERKIN-ELMER CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1999027020-A1 | DIBENZORHODAMINE DYES USEFUL AS FLOURESCENT LABELLING AGENTS | THE PERKIN-ELMER CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020034761-A1 | Methods of labelling polynucleotides with dibenzorhodamine dyes | NUDT1, DUT, NSUN2 | NQO2 242/4885CYP1A2 3124/4885CYP2A6 2301/4885 |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | NQO2 964/4885CYP1A2 3676/4885CYP2A6 3703/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | NQO2 1350/4885CYP1A2 4159/4885CYP2A6 3178/4885 |
| US-20010011139-A1 | Polynucleotides labeled with dibenzorhodamine dyes | NUDT1, DNTT, DUT | NQO2 54/4885CYP1A2 2069/4885CYP2A6 2106/4885 |
| US-12612387-B2 | RAS inhibitors and methods of using the same | KRAS, NRAS, HRAS | NQO2 1033/4885CYP1A2 4141/4885CYP2A6 1698/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | NQO2 717/4885CYP1A2 3571/4885CYP2A6 3049/4885 |
| US-20180282257-A1 | Aromatic Monoester Compositions and Processes for Preparing Same | ADH1A, ADH1C, GK | NQO2 4152/4885CYP1A2 88/4885CYP2A6 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.